Chiara Cp Pesenti

List of Publications by Year
in descending order

		933264	794469
20 papers	363 citations	10 h-index	19 g-index
20 all docs	20 docs citations	20 times ranked	643 citing authors

#	Article	IF	Citations
1	Mismatch Repair Protein Loss as a Prognostic and Predictive Biomarker in Breast Cancers Regardless of Microsatellite Instability. JNCI Cancer Spectrum, 2018, 2, pky056.	1.4	71
2	Prognostic value of preoperative von Willebrand factor plasma levels in patients with Glioblastoma. Cancer Medicine, 2016, 5, 1783-1790.	1.3	34
3	Impact of Mutation Density and Heterogeneity on Papillary Thyroid Cancer Clinical Features and Remission Probability. Thyroid, 2019, 29, 237-251.	2.4	31
4	The Genetic Landscape of Human Glioblastoma and Matched Primary Cancer Stem Cells Reveals Intratumour Similarity and Intertumour Heterogeneity. Stem Cells International, 2019, 2019, 1-12.	1.2	29
5	PTEN Expression as a Complementary Biomarker for Mismatch Repair Testing in Breast Cancer. International Journal of Molecular Sciences, 2020, 21, 1461.	1.8	25
6	Constitutive BRCA1 Promoter Hypermethylation Can Be a Predisposing Event in Isolated Early-Onset Breast Cancer. Cancers, 2019, 11, 58.	1.7	22
7	*MGMT-*Methylated Alleles Are Distributed Heterogeneously Within Glioma Samples Irrespective of *IDH* Status and Chromosome 10q Deletion. Journal of Neuropathology and Experimental Neurology, 2016, 75, 791-800.	0.9	19
8	Mass spectrometry-based assay for the molecular diagnosis of glioma: concomitant detection of chromosome 1p/19q codeletion, and IDH1, IDH2, and TERT mutation status. Oncotarget, 2017, 8, 57134-57148.	0.8	17
9	Reduced kinase activity of polo kinase Cdc5 affects chromosome stability and DNA damage response in *S. cerevisiae*. Cell Cycle, 2016, 15, 2906-2919.	1.3	16
10	Molecular profiling of lung cancer specimens and liquid biopsies using MALDI-TOF mass spectrometry. Diagnostic Pathology, 2018, 13, 4.	0.9	16
11	MassARRAY-based simultaneous detection of hotspot somatic mutations and recurrent fusion genes in papillary thyroid carcinoma: the PTC-MA assay. Endocrine, 2018, 61, 36-41.	1.1	13
12	Analysis of BRCA1 and RAD51C Promoter Methylation in Italian Families at High-Risk of Breast and Ovarian Cancer. Cancers, 2020, 12, 910.	1.7	13
13	Germline oncopharmacogenetics, a promising field in cancer therapy. Cellular Oncology (Dordrecht), 2015, 38, 65-89.	2.1	11
14	Biological and clinical features of triple negative Invasive Lobular Carcinomas of the breast. Clinical outcome and actionable molecular alterations. Breast, 2021, 59, 94-101.	0.9	11
15	Detection of *TP53* Clonal Variants in Papanicolaou Test Samples Collected up to 6 Years Prior to High-Grade Serous Epithelial Ovarian Cancer Diagnosis. JAMA Network Open, 2020, 3, e207566.	2.8	10
16	A novel splice site variant in *ITPR1* gene underlying recessive Gillespie syndrome. American Journal of Medical Genetics, Part A, 2018, 176, 1427-1431.	0.7	9
17	Copy number alterations in stage I epithelial ovarian cancer highlight three genomic patterns associated with prognosis. European Journal of Cancer, 2022, 171, 85-95.	1.3	8
18	Revertant mosaicism for family mutations is not observed in BRCA1/2 phenocopies. PLoS ONE, 2017, 12, e0171663.	1.1	7

#	Article	IF	Citations
19	IMP3 expression in NSCLC brain metastases demonstrates its role as a prognostic factor in non-neuroendocrine phenotypes. Medical Oncology, 2018, 35, 2.	1.2	1
20	Biological and clinical features of early triple-negative invasive lobular carcinomas of the breast.. Journal of Clinical Oncology, 2020, 38, e12570-e12570.	0.8	0